BIOX Announces 2017 Third Quarter Results

TSX symbol: BX

TORONTO, Aug. 8, 2017 /CNW/ - BIOX Corporation (BIOX) (TSX: BX), a renewable energy company that owns and operates biodiesel production facilities, today announced its 2017 third quarter financial results for the three-month (Q3 2017) and nine-month periods ended June 30, 2017.

Highlights

  • Production of 16.4 million litres of methylesters at the Hamilton facility and 14.5 million litres of biodiesel at the WEBB facility in Q3 2017
  • Sales were $19,031,000 in Q3 2017
  • Operating loss prior to non-cash items1 was $1,057,000 in Q3 2017
  • Net loss was $3,313,000 in Q3 2017
  • Net loss per basic share was $0.07 in Q3 2017
  • The Board of Directors received, and recommended shareholders vote in favour of, an offer of $1.23 per common share from a principal shareholder to acquire all outstanding shares of the Company
  • Subsequent to the end of the quarter, management and the Board of Directors made a decision to defer the completion of the upgrades at the Sombra facility pending the outcome of the shareholder vote on the announced offer

"Our Hamilton facility continues to operate at the top end of our targeted range and the Houston facility continued to perform well throughout the quarter. Demand for our low carbon intensity biodiesel remains strong in Ontario due to the Greener Diesel program, however the U.S. market remains challenging due to tighter margins and uncertainty related to the U.S. biodiesel tax incentive and the 2018 Renewable Volume Obligation," said Alan Rickard, Chief Executive Officer of BIOX. "We encourage all shareholders to vote their shares at the upcoming special meeting of shareholders that will consider the offer from a principal shareholder to acquire all outstanding shares of the Company. We intend to file the Management Information Circular in the coming days for the meeting which is scheduled for September 7, 2017. The Board of Directors has recommended shareholders vote in favour of the offer."

Financial Highlights
Sales were $19.0 million and $52.8 million for the three-month (Q3 2017) and the nine-month (YTD 2017) periods ended June 30, 2017, respectively, compared to $39.7 million and $86.8 million for the corresponding periods in fiscal 2016. The change in each period is primarily due to the sale of substantial volumes of third party product in fiscal 2016 described below. The change in the YTD period is also partially due to the recognition of US$6.7 million of refundable tax credits from customers and the U.S. Internal Revenue Service related to the retroactive reinstatement of the U.S. biodiesel tax incentive in YTD 2016.

BIOX sold 16.1 million litres and 45.0 million litres of biodiesel in Q3 2017 and YTD 2017, respectively, compared to 34.8 million litres and 78.2 million litres in the corresponding periods in fiscal 2016. The changes in sales and volume sold for both Q3 2017 and YTD 2017 are primarily due to lower sales of third-party product. The Company sold less than 0.2 million litres and 0.3 million litres of third-party product in Q3 2017 and YTD periods, respectively, compared to 22.1 million litres and 32.8 million litres of third-party product sales in the corresponding periods in fiscal 2016.

Direct expenses were $18.5 million and $52.2 million for Q3 2017 and YTD 2017, respectively, compared to $37.6 million and $78.8 million for the corresponding periods in fiscal 2016. The changes are primarily the result of the reduction in purchases of third-party product, partially offset by an increase in the average price of feedstock over the prior year periods.

General and administrative expenses were $1.6 million and $4.8 million for Q3 2017 and YTD 2017, respectively, compared to $1.0 million and $3.8 million for the corresponding periods in fiscal 2016. The changes were primarily due to an increase in professional fees related to management's growth strategies and work related to the Special Committee of the Board in Q3 2017.

Operating loss was $1.8 million and $6.5 million for Q3 2017 and YTD 2017, respectively, compared to operating income of $0.1 million and $1.5 million for the corresponding periods in fiscal 2016. The change in the quarterly period is primarily due to the expiry of the U.S. biodiesel tax incentive which resulted in lower relative sales revenue in Q3 2017. The change in the YTD period is primarily a result of the collection of $9.2 million in refundable tax credits, referenced above, related to the reinstatement of the U.S. biodiesel tax incentive in YTD 2016. There was no such revenue recognized in the corresponding period in fiscal 2017.     

Operating loss prior to non-cash items1 was $1.0 million and $4.2 million for Q3 2017 and YTD 2017, respectively, compared to an operating income prior to non-cash items of $0.9 million and $4.2 million for the corresponding periods in fiscal 2016. The changes in the respective periods are related to the same items referenced in the operating loss section above.   

Net loss was $3.3 million and $11.6 million for Q3 2017 and YTD 2017, respectively, compared to $0.9 million and $1.8 million for the corresponding periods in fiscal 2016. Net loss per basic share was $0.07 and $0.25 for Q3 2017 and YTD 2017, respectively, compared to $0.02 and $0.04 for the corresponding periods in fiscal 2016. The change in the quarterly period is primarily due to the expiry of the U.S. biodiesel tax incentive which resulted in lower relative sales revenue in Q3 2017. The change in the YTD period is also related to the retroactive reinstatement of the U.S. biodiesel tax incentive referenced above.

As at June 30, 2017, BIOX's available cash position and working capital was $2.1 million and negative $24.2 million, respectively, compared with $3.5 million and negative $6.1 million at September 30, 2016. The decrease in working capital is primarily due to the receipt of additional short-term funding for the upgrades to the Sombra facility, as well as, the reclassification of promissory notes from long-term to short-term as they mature twelve months from the end of June 30, 2017.

As at June 30, 2017, BIOX had 46,325,544 common shares outstanding, as well as outstanding options to purchase up to 1,430,000 common shares of BIOX and outstanding warrants to purchase up to 4,400,000 common shares of BIOX.

Sombra Update
Management and the Board of Directors have decided to defer the completion of the upgrades at Sombra facility pending a review of the circumstances after the upcoming shareholder vote on September 7, 2017. Given the combination of a narrow margin environment, constrained cash flows from operations and the level of uncertainty in the U.S. biodiesel market, the Company felt the best decision was to defer the balance of the capital spend and the commissioning plans. The facility was purchased based on the strength of the Ontario Greener Diesel program and the Company remains committed to having the facility in full operation in time for the main blending season in 2018.

Special Meeting of Shareholders
In July 2017, BIOX announced that it had signed a definitive arrangement agreement to go private.  Under the arrangement agreement, FP Resources Limited and CFFI Ventures Inc. (collectively, the "Acquiror Group") through 10293547 Canada Limited (the "Purchaser"), a wholly-owned indirect subsidiary of CFFI Ventures, would acquire all of the outstanding common shares of the common shares not already owned by the Acquiror Group for cash consideration of $1.23 per common share through a court approved plan of arrangement under the Canada Business Corporations Act.

The Company will hold a special meeting of its shareholders on September 7, 2017, to seek approval for the arrangement.  The Management Information Circular and related meeting material will be made available 21 days prior to the meeting.

Based on the unanimous recommendation of a Special Committee of the Board, formed to assess the proposed transaction and comprised entirely of independent directors, the Board of Directors of the Company has, with interested directors abstaining: (i) determined that the proposed arrangement agreement is fair to minority shareholders and that it is in the best interests of the Company; and (ii) recommended that shareholders vote in favour of the arrangement agreement.

Reconciliation of Non-IFRS Measures1
The following table presents a reconciliation of operating income prior to non-cash items to net income for the three-month and nine-month periods ended June 30, 2017 and 2016:

(in thousands)

Three months ended

Nine months ended

June 30

June 30


2017

2016

2017

2016


$

$

$

$

Operating (loss) income before non-cash items

(1,057)

939

(4,186)

4,192






Deduct:

Production facility depreciation and amortization

(617)

(673)

(2,018)

(2,110)







Depreciation and amortization of equipment and intangible assets          

(47)

(54)

(149)

(166)







Share-based compensation

(33)

(99)

(117)

(356)







Provision for unutilized tank storage

(17)

(21)

(17)

(21)

Operating (loss) income

(1,771)

92

(6,487)

1,539

Income tax expense

(308)

(798)

(1,075)

(2,537)

Other income and expenses

(1,234)

(195)

(4,077)

(844)

Net loss 

(3,313)

(901)

(11,639)

(1,842)






1)

Note: Non-IFRS Measures. Operating income (loss) prior to non-cash items is defined as operating income or loss less production facility depreciation and amortization, and less depreciation and amortization of equipment and intangibles and share-based compensation. Management uses this measurement to monitor the operating cash flow of BIOX's business and believes this information is useful supplemental information to a reader of financial statements. This measurement may not be comparable to similar measures presented by other issuers. Investors are cautioned that operating income (loss) prior to non-cash items should not be construed as an alternative to net (loss) income determined in accordance with IFRS as an indicator of BIOX's performance.

 

About BIOX Corporation
BIOX is a renewable energy company that, owns and operates 287.5 million litres of nameplate biodiesel production capacity at plants located in Houston, Texas and two facilities in southern Ontario. BIOX has an innovative, proprietary and patented production process that is capable of producing the highest quality, renewable, clean burning and biodegradable biodiesel fuel utilizing a variety of feedstocks - from pure seed oils to animal fats to recovered vegetable oils with no change to the production process. BIOX's high quality biodiesel fuel meets North American (ASTM D-6751) quality standards.

Forward-looking Statements
Certain statements in this press release constitute "forward-looking" statements that involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, objectives or achievements of the Company, or industry results, to be materially different from any future results, performance, objectives or achievements expressed or implied by such forward-looking statements.  These statements reflect BIOX's current views regarding future events and operating performance and are based on information currently available to BIOX, and speak only as of the date of this MD&A. These forward–looking statements involve a number of risks, uncertainties and assumptions and should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not such performance or results will be achieved. Those assumptions and risks include, but are not limited to, the fact that BIOX's results of operations and business outlook are highly dependent on a mix of legislation and producer payment programs and tax credits, and commodity prices, all of which are subject to significant volatility and uncertainty and current expectations of management of BIOX regarding the Arrangement (as hereinafter defined) and its consummation, including whether the conditions to the consummation of the Arrangement will be satisfied and the timing for completion. There can be no assurance that forward looking statements will be accurate as many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including factors described in this MD&A and those discussed in BIOX's publicly available disclosure documents, as filed by BIOX on SEDAR (www.sedar.com) and updated herein. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described in this MD&A as intended, planned, anticipated, believed, estimated or expected. Accordingly, readers should not place undue reliance on forward looking statements.  All subsequent forward looking statements, whether written or oral, attributable to BIOX or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Unless required by applicable securities law, BIOX does not intend and does not assume any obligation to update these forward-looking statements.

BIOXCorporation

Condensed consolidated interim statements of comprehensive loss

Three and nine month periods ended June 30, 2017 and 2016

(Unaudited)

(Expressed in thousands of Canadian dollars, except share and per share amounts)





 Three months ended 


 Nine months ended






 June 30 



 June 30 





2017

2016


2017

2016





$

$


$

$










Revenue

19,031

39,663


52,762

86,832










Cost of sales







Direct expenses

18,485

37,580


52,183

78,757


Production facility depreciation and amortization

617

673


2,018

2,110





19,102

38,253


54,201

80,867










Gross margin

(71)

1,410


(1,439)

5,965










Operating expenses







General and administrative

1,603

1,012


4,765

3,751


Depreciation and amortization of equipment








 and intangible assets

47

54


149

166


Share-based compensation

33

99


117

356


Expansion planning and development

17

153


17

153





1,700

1,318


5,048

4,426










Operating (loss) income

(1,771)

92


(6,487)

1,539










Other expenses







Financing costs

890

525


2,575

992


Loss on investment in joint venture

268

-


1,379

-


Gain on revaluation of asset retirement obligation

-

-


-

(329)


Foreign exchange loss (gain)

78

(330)


132

197





1,236

195


4,086

860










Net (loss) income before interest income and income taxes

(3,007)

(103)


(10,573)

679

Income tax expense

(308)

(798)


(1,075)

(2,537)

Interest income

2

-


9

16

Net loss for the period

(3,313)

(901)


(11,639)

(1,842)

Other comprehensive income







Foreign currency translation gain

145

5


94

62

Comprehensive loss

(3,168)

(896)


(11,545)

(1,780)










Loss per common share







Basic

(0.07)

(0.02)


(0.25)

(0.04)


Diluted

(0.07)

(0.02)


(0.25)

(0.04)










Weighted average number of common







shares outstanding







Basic

46,183,043

46,069,404


46,183,043

46,069,404


Diluted

46,183,043

46,069,404


46,183,043

46,069,404

 

BIOXCorporation

Condensed consolidated interim statements of changes in equity

Nine month periods ended June 30, 2017 and 2016

(Unaudited)

(Expressed in thousands of Canadian dollars, except share and per share amounts)





 Common share capital 


 Warrant reserve 




 Accumulated 













 Share 






 other 













 purchase 




 Equity 


 comprehensive 




 Total 





 Shares 


 Amount 


 warrants 


 Amount 


 reserve 


 loss 


 Deficit 


 equity 





 # 


$


 # 


$


$


$


$


$




















Balance, September 30, 2015

46,025,124


168,130


-


-


1,968


(659)


(136,474)


32,965

Share-based compensation

-


-


-


-


356


-


-


356

Share purchase

72,919


46


-


-


(20)


-


-


26

Net loss

-


-


-


-


-


-


(1,842)


(1,842)

Foreign currency translation gain

-


-


-


-


-


62


-


62

Balance, June 30, 2016

46,098,043


168,176


-


-


2,304


(597)


(138,316)


31,567




















Balance, September 30, 2016 

46,098,043


168,176


4,400,000


727


2,446


(617)


(139,883)


30,849

Share-based compensation

-


-


-


-


117


-


-


117

Share purchase

227,501


248


-


-


(112)


-


-


136

Net loss

-


-


-


-


-


-


(11,639)


(11,639)

Foreign currency translation gain

-


-


-


-


-


94


-


94

Balance, June 30, 2017

46,325,544


168,424


4,400,000


727


2,451


(523)


(151,522)


19,557




















 

BIOXCorporation

Condensed consolidated interim statements of financial position

As at June 30, 2017 and September 30, 2016

(Unaudited)

(Expressed in thousands of Canadian dollars)






 June 30, 

 September 30, 





2017

2016





$

$

Assets



Current assets




Cash and cash equivalents

2,102

3,529


Restricted cash

1,174

1,174


Accounts receivable

1,890

2,882


Prepaid expenses

529

808


Inventory

4,294

3,841





9,989

12,234







Investment in joint venture

11,539

12,984

Property, plant and equipment

32,575

30,091

Intangible assets

232

304

Deferred income tax assets

8,911

9,985





63,246

65,598







Liabilities



Current liabilities




Accounts payable and other liabilities

8,528

7,108


Demand loan

3,461

-


Short-term debt

14,023

8,330


Secured promissory notes

5,948

-


Current portion of long-term debt

1,500

1,500


Current portion of finance leases

-

6


Current portion of provisions

731

1,432





34,191

18,376







Long-term debt

5,987

7,107

Secured promissory notes

-

5,570

Provisions

3,511

3,696





43,689

34,749







Equity



Common share capital

168,424

168,176

Warrant reserve

727

727

Equity reserve

2,451

2,446

Accumulated other comprehensive loss

(523)

(617)

Deficit

(151,522)

(139,883)





19,557

30,849





63,246

65,598







 

BIOXCorporation

Condensed consolidated interim statements of cash flows

Nine month periods ended June 30, 2017 and 2016

(Unaudited)

(Expressed in thousands of Canadian dollars, except share and per share amounts)





2017

2016





$

$

Operating activities




Net loss

(11,639)

(1,842)


Add (less) items not involving cash





Production facility depreciation and amortization

2,018

2,110



Depreciation and amortization of equipment and intangible assets

149

166



Financing costs

2,678

280



Provision for unutilized tank storage

17

21



Share-based compensation

117

356



Gain on revaluation of provisions 

-

(329)



Accretion of provisions

185

226



Loss on investment in joint venture

1,343

-



Income tax expense

1,075

2,537





(4,057)

3,525








Net change in non-cash working capital balances





related to operations

1,958

(109)





(2,099)

3,416







Investing activity




Purchase of property, plant and equipment

(4,315)

(6,899)


Investment in joint venture

-

(14,044)


Decrease in restricted cash

-

(914)





(4,315)

(21,857)







Financing activities




Payments on tank lease provision

(1,113)

(1,130)


Payments on finance leases

(6)

(23)


Proceeds from debt financing

5,000

12,917


Repayment of long-term debt financing

(1,125)

(1,125)


Proceeds from demand loan

3,461

510


Issuance of common shares

136

26


Interest paid

(1,161)

(276)





5,192

10,899







Effect of exchange rate changes on:




Cash held in foreign currency

(205)

418







Net decrease in cash and cash equivalents during the period

(1,427)

(7,124)

Cash and cash equivalents, beginning of period

3,529

7,709

Cash and cash equivalents, end of period

2,102

585







SOURCE BIOX Corporation

For further information: Alan Rickard, CEO, BIOX Corporation, 905-521-8205 ext. 253, arickard@bioxcorp.com

Organization Profile

BIOX Corporation

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890